Business Development Overview

GeNO’s new stand-alone gas cylinder platform for hospital use, the pocket-sized ambulatory platform for chronic outpatient use, together with the ventilator-based platform for Intensive Care Unit (ICU) use open up many new opportunities for the delivery of inhaled nitric oxide.

GeNO has identified more than 20 possible indications for the GeNO nitric oxide delivery platforms where the indications are already in clinical trials or where the proof of concept with inhaled nitric oxide has already been established (ClinicalTrials.gov).

Clinical Development